PHILADELPHIA and VANCOUVER, British Columbia, May 15, 2026
BriaCell Therapeutics announced the expansion of its oncology pipeline with the development of Bria-OVA+™, a next-generation personalized immunotherapy candidate targeting ovarian cancer, one of the deadliest gynecologic malignancies worldwide. The move strengthens BriaCell’s growing focus on women’s health and builds on encouraging Phase 2 clinical results previously reported for its metastatic breast cancer immunotherapy platform. According to the company, Bria-OVA+ is being developed as an off-the-shelf, cell-based immunotherapy designed with additional immune-stimulating components intended to enhance anti-tumor activity in patients with difficult-to-treat ovarian cancer.
BriaCell stated that the ovarian cancer program leverages the same Bria-OTS+™ platform technology supporting its breast cancer pipeline. Management believes the platform’s ability to activate multiple immune system pathways could potentially offer a differentiated therapeutic approach compared with currently available ovarian cancer treatments. The company has already licensed ovarian cancer cell lines from the American Type Culture Collection (ATCC) and initiated development activities aimed at preparing Bria-OVA+ for potential future clinical evaluation. Executives described the expansion as part of a broader long-term strategy to establish BriaCell as a major innovator in personalized immunotherapies for women’s cancers.
Bria-OVA+ Designed to Enhance Anti-Tumor Immune Response
BriaCell highlighted that Bria-OVA+ incorporates additional immune-stimulating features intended to strengthen both innate and adaptive immune responses against ovarian tumors. The company’s confidence in the platform was reinforced by recent preclinical findings involving Bria-BRES+™, its next-generation breast cancer immunotherapy candidate derived from the same underlying technology. During a recent presentation at the American Association for Cancer Research (AACR) meeting, Bria-BRES+ demonstrated activation of resting T cells, dendritic cells, and natural killer (NK) cells, suggesting broad immune engagement across multiple anti-cancer pathways.
Company leadership believes these immune activation characteristics may also translate into ovarian cancer applications, particularly in patients who fail standard therapies. Current ovarian cancer treatment options typically include surgery, platinum-based chemotherapy, PARP inhibitors such as Lynparza, and antibody-drug conjugates like Elahere. However, many ovarian cancer patients eventually develop resistance or experience severe side effects, creating substantial unmet medical need. BriaCell’s management stated that Bria-OVA+ is being positioned as a potentially differentiated immunotherapy option capable of generating durable anti-tumor immune activity while maintaining tolerability.
Ovarian Cancer Remains a Major Unmet Medical Need
Advertisement
According to data referenced by BriaCell from the National Cancer Institute, approximately 21,010 women are expected to be diagnosed with ovarian cancer in the United States during 2026, while nearly 12,450 deaths are projected from the disease. Ovarian cancer remains the leading cause of death among gynecologic cancers due largely to late-stage diagnosis, treatment resistance, and limited long-term therapeutic options.
BriaCell executives emphasized that many ovarian cancer patients continue to face poor outcomes despite recent advancements in targeted therapies. By combining personalized immunotherapy approaches with scalable off-the-shelf manufacturing strategies, the company aims to develop treatments capable of improving survival while expanding access to advanced immuno-oncology care. The Bria-OVA+ initiative also represents a strategic expansion beyond breast cancer into broader gynecologic oncology markets where innovative immunotherapies remain relatively limited compared with other oncology sectors.
As competition intensifies in the immuno-oncology landscape, BriaCell’s progress with Bria-OVA+ will likely be closely monitored by investors and clinicians seeking new approaches for ovarian cancer patients with limited treatment alternatives.
Source: BriaCell Therapeutics press release
